REFERENCES
- Owens P, Kelly L, Nallen R, Ryan D, Fitzgerald D, O'Brien E. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide—a randomized controlled trial. J Hypertens 2000; 18: 339–345, [PUBMED], [INFOTRIEVE]
- Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1999; 44: 89–99, [CROSSREF]
- Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281: 1065–1070, [PUBMED], [INFOTRIEVE]
- Maeso R, Rodrigo E, Muñoz-Garcia R, Navarro-Cid J, Ruilope LM, Lahera V, Cachofeiro V. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. J Hypertens 1997; 15: 1677–1684, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994; 268: 747–752, [PUBMED], [INFOTRIEVE]
- Yamamoto Y, Kamiya K, Terao S. Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction. J Med Chem 1993; 36: 820–825, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992; 573: 295–301, [PUBMED], [INFOTRIEVE]
- Boarder MR, Hourani SM. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol Sci 1998; 19: 99–107, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36: 281–306, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Findlay J, Eliopoulos E. Three-dimensional modeling of G protein-linked receptors. Trends Pharmacol Sci 1990; 11: 492–99, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharm 1998; 32: 198–205, [CROSSREF]
- Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188–92, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA, Garcia R, Gomez J, Farre J, Casado S, Lopez-Farre A. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–452, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Boger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 19;90(7)770–776, [CROSSREF]
- Andrioli G, Ortolani R, Fontana L, Gaino S, Bellavite P, Lechi C, Minuz P, Manzato F, Tridente G, Lechi A. Study of platelet adhesion in patients with uncomplicated hypertension. J Hypertens 1996; 14: 1215–21, [PUBMED], [INFOTRIEVE]